论文部分内容阅读
目的 比较中晚期原发性肝癌患者单纯行肝动脉化学药物栓塞 (TACE)及加用褪黑素(MLT)的临床效果。方法 1997年 1月至 1998年 1月收治 10 0例不能 1期手术的中晚期肝癌病人 ,TACE治疗组 5 0例 ;MLT +TACE组 5 0例 ,在TACE治疗前 1周起开始口服MLT 2 0mg/d。结果 两组近期有效率 (WHO标准 )分别为 16% ( 8/5 0 )和 2 8% ( 14 /5 0 ) (P <0 0 5 ) ,0 5年、1年及 2年生存率TACE组分别为 82 % ( 4 1/5 0 )、5 4 % ( 2 7/5 0 )和 2 6% ( 13 /5 0 ) ,MLT +TACE组分别为 10 0 % ( 5 0 /5 0 )、68% ( 3 4 /5 0 )及 4 0 % ( 2 0 /5 0 ) ,两组比较MLT +TACE组疗效明显优于单纯TACE组 (P均 <0 0 5 )。MLT可使TACE治疗后患者外周血IL 2的含量提高及SIL 2R的表达降低 (P <0 0 1)。结论 MLT可增强患者的免疫保护 ,提高TACE的疗效 ,延长患者的生存期。
Objective To compare the clinical effects of hepato-artery chemical embolization (TACE) and melatonin (MLT) in patients with advanced primary liver cancer. Methods From January 1997 to January 1998, a total of 100 patients with advanced stage hepatic carcinoma who were unable to undergo primary surgery were included. 50 patients in the TACE treatment group and 50 patients in the MLT + TACE group were treated with oral MLT 2 starting 1 week before TACE treatment. 0mg/d. The results of the two groups of recent effective rates (WHO criteria) were 16% (8/5 0) and 2 8% (14 /5 0) (P <0 05), 0 5 years, 1 year and 2 year survival rates TACE The group was 82% (4 1/5 0), 5 4 % (2 7/5 0) and 2 6% (13 /5 0) respectively, and the MLT +TACE group was 100% (50/50%) respectively. , 68% (3 4 /5 0) and 4 0 % ( 2 0 /5 0 ), the efficacy of MLT + TACE group was significantly better than that of TACE alone (P <0 05). MLT increased IL 2 levels and SIL 2R expression in peripheral blood of patients after TACE (P < 0.01). Conclusion MLT can enhance the immune protection of patients, improve the efficacy of TACE, and prolong the survival of patients.